Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study | Synapse
March 3, 2026Open Access
Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study
Puntos clave
Evinacumab notably improves cholesterol levels in patients with homozygous familial hypercholesterolaemia, indicating a strong therapeutic effect.
The study reveals that genotypes affect the response to evinacumab, with some patients experiencing greater LDL reduction.
Subanalysis from the ELIPSE open-label extension study provided insights into the role of low-density lipoprotein receptor function.
These findings highlight the need for personalized treatment strategies to optimize cholesterol-lowering therapies.